REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in preclinical models of asthma, acute lung inflammation and ...
Aldeyra submitted the single successful trial to the FDA over the summer and the agency accepted the resubmitted NDA for ...
Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated pharmaceutical company, announced today that the U.S. Food and ...
(ASG), a leader in the research and development of novel inhaled drugs, today announced that its lead product, Beta1, has received Investigational New Drug (IND) application clearance from the U.S.
The FDA announced that it removed a limitation on the use of real-world evidence (RWE) in drug and device application reviews ...
GlobalData on MSN
High-value oncology deals drive China’s drug licensing boom
China’s focus on first or best-in-class oncology drugs and innovative R&D will position it well in 2026 and beyond.
Northeastern University researchers have made a breakthrough drug discovery, developing the first synthetic endogenous ...
The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for Aldeyra’s New Drug Application (NDA) for reproxalap for the treatment of dry ...
Drug cartels are producing a cheaper form of a lethal drug and DEA officials here in the metro say the stuff has made its way ...
Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology ...
Overcoming acquired treatment resistance is one of the major challenges in the fight against cancer. While combination ...
The FDA taps J&J drug teclistamab for its National Priority Voucher pilot, enabling expedited review for multiple myeloma treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback